Document is current
Any future updates will be listed below
-
Authors
Stegmann, Jens-Ulrich
Jusot, Viviane https://orcid.org/0000-0002-7747-8788
Menang, Olga
Gardiner, Gregory
Vesce, Sabino
Volpe, Stephanie
Ndalama, Anderson
Adou, Felix
Ofori-Anyinam, Opokua
Oladehin, Olakunle
Mendoza, Yolanda Guerra
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 13 August 2021
Accepted: 25 July 2022
First Online: 17 August 2022
Declarations
:
: All individual data was handled by the Ministries of Health of the participating countries, and the content of the present publication only pertains to the evaluation of the pharmacovigilance enhancement initiative. Hence, neither an ethics committee approval nor consent to participate were deemed necessary.
: Not applicable.
: JUS, VJ, SV1, OOA, OO, and YGM are employees of the GSK group of companies. GG and SV2 were employed by the GSK group of companies during the conduct of this project. JUS, VJ, OOA, OO, and YGM hold shares in the GSK group of companies. OM, AN and FA report no conflict of interest. All authors have no non-financial interests to declare.
